Skip to main content

Advertisement

SpringerLink
Log in

CD40/CD40L system and vascular disease

  • Review
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Several distinct lines of investigation in the context of atherosclerosis dealing with low-grade inflammation, oxidative stress and platelet activation are now emerging, with CD40/CD40L system as the missing link. CD40 ligand is a transmembrane glycoprotein structurally related to tumour necrosis factor-α and more than 95% of the circulating CD40L derives from platelets. CD40L appears as a multiplayer of several cell types in the inflammatory network. The peculiarity of CD40L as an inflammatory mediator derived from platelets expands the functional repertoire of platelets from players of haemostasis and thrombosis to powerful amplifiers of inflammation by promoting the release of cytokines and chemokines, cell activation and cell-cell interactions. The multifunctional role of CD40L, as a simultaneous activator of all these systems, further blurs the intricate relationship between such events both in the physiological systems and the pathological derangement occurring in atherothrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Armitage RJ, Fanslow WC, Strockbine L et al (1992) Molecular and biological characterization of a murine ligand for CD40. Nature 357:80–82

    PubMed  CAS  Google Scholar 

  2. Lederman S, Yellin MJ, Krichevsky A et al (1992) Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med 175:1091–1101

    PubMed  CAS  Google Scholar 

  3. Gauchat JF, Henchoz S, Mazzei G et al (1993) Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 365:340–343

    PubMed  CAS  Google Scholar 

  4. Henn V, Slupsky JR, Gräfe M et al (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591–594

    PubMed  CAS  Google Scholar 

  5. Schönbeck U, Libby P (2001) The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 58:4–43

    PubMed  Google Scholar 

  6. Henn V, Steinbach S, Büchner K et al (2001) The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98:1047–1054

    PubMed  CAS  Google Scholar 

  7. Andre P, Prasad KS, Denis CV et al (2002) CD40L stabilizes arterial thrombi by a b3 integrin-dependent mechanism. Nat Med 8:247–252

    PubMed  CAS  Google Scholar 

  8. Nannizzi-Alaimo L, Alves VL, Phillips DR (2003) Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 107:1123–1128

    PubMed  CAS  Google Scholar 

  9. Otterdal K, Pedersen TM, Solum NO (2004) Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase. Thromb Res 114:167–177

    PubMed  CAS  Google Scholar 

  10. Furman MI, Krueger LA, Linden MD et al (2004) Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 43:2326–2328

    Google Scholar 

  11. Inwald DP, McDowall A, Peters MJ et al (2003) CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 92:1041–1048

    PubMed  CAS  Google Scholar 

  12. Prasad KS, Andre P, He M et al (2003) Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A 100:12367–12371

    PubMed  CAS  Google Scholar 

  13. Furman MI, Krueger LA, Linden MD et al (2005) GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost 3:312–320

    PubMed  CAS  Google Scholar 

  14. Lutgens E, Daemen MJ (2002) CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 12:27–32

    PubMed  CAS  Google Scholar 

  15. Zhou L, Stordeur P, de Lavareille A et al (1998) CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost 79:1025–1028

    PubMed  CAS  Google Scholar 

  16. Schönbeck U, Mach F, Sukhova GK et al (2000) CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 156:7–14

    PubMed  Google Scholar 

  17. Lindmark E, Tenno T, Siegbahn A (2000) Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 20:2322–2328

    PubMed  CAS  Google Scholar 

  18. Chakrabarti S, Varghese S, Vitseva O et al (2005) CD40 lig-and influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 25:2428–2434

    PubMed  CAS  Google Scholar 

  19. Zirlik A, Maier C, Gerdes N et al (2007) CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 115:1571–1580

    PubMed  CAS  Google Scholar 

  20. Chai H, Yan S, Wang H et al (2006) CD40 ligand increases expression of its receptor CD40 in human coronary artery endothelial cells. Surgery 140:236–242

    PubMed  Google Scholar 

  21. Aukrust P, Muller F, Ueland T et al (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100:614–620

    PubMed  CAS  Google Scholar 

  22. Heeschen C, Dimmeler S, Hamm CW et al; CAPTURE Study Investigators (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348:1104–1111

    PubMed  CAS  Google Scholar 

  23. Marx N, Imhof A, Froelich J et al (2003) Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107:1954–1957

    PubMed  CAS  Google Scholar 

  24. Nannizzi-Alaimo L, Rubenstein MH, Alves VL et al (2002) Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 105:2849–2854

    PubMed  CAS  Google Scholar 

  25. Cipollone F, Ferri C, Desideri G et al (2003) Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 108:2776–2782

    PubMed  CAS  Google Scholar 

  26. Turker S, Guneri S, Akdeniz B et al (2006) Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol 97:198–202

    PubMed  Google Scholar 

  27. Urbich C, Dernbach E, Aicher A et al (2002) CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 106:981–986

    PubMed  CAS  Google Scholar 

  28. Varo N, de Lemos JA, Libby P et al (2003) Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108:1149–1152

    Google Scholar 

  29. Antoniades C, Tousoulis D, Vasiliadou C et al (2006) Genetic polymorphisms of platelet glycoprotein Ia and the risk for premature myocardial infarction: effects on the release of sCD40L during the acute phase of premature myocardial infarction. J Am Coll Cardiol 47:1959–1966

    PubMed  CAS  Google Scholar 

  30. Malarstig A, Lindahl B, Wallentin L, Siegbahn A (2006) Soluble CD40L levels are regulated by the −3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol 26:1667–1673

    PubMed  Google Scholar 

  31. Blake GJ, Ostfeld RJ, Yucel EK et al (2003) Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high resolution MRI. Arterioscler Thromb Vasc Biol 23:e11–e14

    PubMed  CAS  Google Scholar 

  32. Novo S, Basili S, Tantillo R et al (2005) Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke 36:673–675

    PubMed  CAS  Google Scholar 

  33. Cha JK, Jeong MH, Jang JY et al (2003) Serial measurement of surface expressions of CD63, P-selectin and CD40 ligand on platelets in atherosclerotic ischemic stroke. A possible role of CD40 ligand on platelets in atherosclerotic ischemic stroke. Cerebrovasc Dis 16:376–382

    PubMed  CAS  Google Scholar 

  34. Garlichs CD, Kozina S, Fateh-Moghadam S et al (2003) Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 34:1412–1418

    PubMed  CAS  Google Scholar 

  35. Grau AJ, Lichy C (2003) Editorial comment: stroke and the CD40-CD40 ligand system: at the hinge between inflammation and thrombosis. Stroke 34:1417–1418

    PubMed  Google Scholar 

  36. Desideri G, Cipollone F, Necozione S et al (2006) Enhanced soluble CD40 ligand and Alzheimer’s disease: evidence of a possible pathogenetic role. Neurobiol Aging Nov 22 [Epub ahead of print]

  37. Lutgens E, Cleutjens KB, Heeneman S et al (2000) Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A 97:7464–7469

    PubMed  CAS  Google Scholar 

  38. Blann AD, Tan KT, Tayebjee MH et al (2005) Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 93:578–583

    PubMed  CAS  Google Scholar 

  39. Herve P, Humbert M, Sitbon O et al (2001) Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 22:451–458

    PubMed  CAS  Google Scholar 

  40. Damas JK, Otterdal K, Yndestad A et al (2004) Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 110:999–1005

    PubMed  CAS  Google Scholar 

  41. Stumpf C, Lehner C, Eskafi S et al (2003) Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 5:629–637

    PubMed  CAS  Google Scholar 

  42. Ueland T, Aukrust P, Yndestad A et al (2005) Soluble CD40 ligand in acute and chronic heart failure. Eur Heart J 26:1101–1107

    PubMed  CAS  Google Scholar 

  43. Gaede P, Vedel P, Larsen N et al (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393

    PubMed  Google Scholar 

  44. Sjoholm A, Nystrom T (2005) Endothelial inflammation in insulin resistance. Lancet 365:610–612

    PubMed  Google Scholar 

  45. Davì G, Ciabattoni G, Consoli A et al (1999) In vivo formation of 8-iso-PGF2a and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224–229

    PubMed  Google Scholar 

  46. Davì G, Catalano I, Averna M et al (1990) Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322:1769–1774

    Article  PubMed  Google Scholar 

  47. Varo N, Vicent D, Libby P et al (2003) Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients. A novel target of thiazolidinediones. Circulation 107:2664–2669

    PubMed  CAS  Google Scholar 

  48. Jinchuan Y, Zonggui W, Jinming C et al (2004) Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta 339:85–90

    PubMed  Google Scholar 

  49. Cabeza N, Li Z, Schulz C et al (2004) Surface expression of collagen receptor Fc receptor-gamma/glycoprotein VI is enhanced on platelets in type 2 diabetes and mediates release of CD40 ligand and activation of endothelial cells. Diabetes 53:2117–2121

    PubMed  CAS  Google Scholar 

  50. Yngen M, Ostenson CG, Hu H et al (2004) Enhanced Pselectin expression and increased soluble CD40 ligand in patients with type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia 47:537–540

    PubMed  CAS  Google Scholar 

  51. Targher G, Zoppini G (2004) Soluble CD40L in young type 1 diabetic individuals without clinical microvascular and macrovascular complications. Diabetes Care 27:1236–1237

    PubMed  Google Scholar 

  52. Katakami N, Kaneto H, Matsuhisa M et al (2006) Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients. Diabetologia 49:1670–1676

    PubMed  CAS  Google Scholar 

  53. Harding SA, Sommerfield AJ, Sarma J et al (2004) Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis 176:321–325

    PubMed  CAS  Google Scholar 

  54. Santilli F, Davì G, Consoli A et al (2006) Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 47:391–397

    PubMed  CAS  Google Scholar 

  55. Lim HS, Blann AD, Lip GY (2004) Soluble CD40 ligand, soluble P-selectin, interleukin-6 and tissue factor in diabetes mellitus. Relationship to cardiovascular disease and risk factor intervention. Circulation 109:2524–2528

    PubMed  CAS  Google Scholar 

  56. Cipollone F, Chiarelli F, Davì G et al (2005) Enhanced soluble CD40 ligand contributes to endothelial cells dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 48:1216–1224

    PubMed  CAS  Google Scholar 

  57. Varo N, Libby P, Nuzzo R et al (2005) Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res 2:81–87

    PubMed  Google Scholar 

  58. Davì G, Averna M, Catalano I et al (1992) Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 85:1792–1798

    PubMed  Google Scholar 

  59. Davì G, Ganci A, Averna M et al (1995) Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. Thromb Hemost 74:247–251

    Google Scholar 

  60. Luomala M, Paiva H, Laaksonen R et al (2006) Plasma-soluble CD40 is related to cholesterol metabolism in patients with moderate hypercholesterolemia. Scand Cardiovasc J 40:280–284

    PubMed  CAS  Google Scholar 

  61. Garlichs CD, John S, Schmeisser A et al (2001) Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104:2395–2400

    PubMed  CAS  Google Scholar 

  62. Cipollone F, Mezzetti A, Porreca E et al (2002) Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 106:399–402

    PubMed  CAS  Google Scholar 

  63. Sanguigni V, Ferro D, Pignatelli P et al (2005) CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia. J Am Coll Cardiol 45:35–42

    PubMed  CAS  Google Scholar 

  64. Sanguigni V, Pignatelli P, Lenti L et al (2005) Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111:412–419

    PubMed  CAS  Google Scholar 

  65. Harding SA, Sarma J, Josephs DH et al (2004) Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation 109:1926–1929

    PubMed  CAS  Google Scholar 

  66. Davì G, Guagnano MT, Ciabattoni G et al (2002) Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288:2008–2014

    PubMed  Google Scholar 

  67. Guldiken B, Guldiken S, Turgut B et al (2007) Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res 120:511–516

    PubMed  CAS  Google Scholar 

  68. Desideri G, Ferri C (2003) Effects of obesity and weight loss on soluble CD40L levels. JAMA 289:1781–1782

    PubMed  Google Scholar 

  69. Basili S, Pacini G, Guagnano MT et al (2006) Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 48:2531–2538

    PubMed  CAS  Google Scholar 

  70. Yan JC, Ma GS, Wu ZG et al (2005) Increased levels of CD40-CD40 ligand system in patients with essential hypertension. Clin Chim Acta 355:191–196

    PubMed  CAS  Google Scholar 

  71. Desideri G, Cipollone F, Valeri L et al (2007) Enhanced plasma soluble CD40 ligand levels in essential hypertensive patients with blunted nocturnal blood pressure decrease. Am J Hypertens 20:70–76

    PubMed  CAS  Google Scholar 

  72. Tsioufis C, Dimitriadis K, Taxiarchou E et al (2006) Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens 19:462–466

    PubMed  CAS  Google Scholar 

  73. Lee WL, Lee WJ, Chen YT et al (2006) The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease. Metabolism 55:1029–1034

    PubMed  CAS  Google Scholar 

  74. Gokulakrishnan K, Deepa R, Mohan V, Gross MD (2006) Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome-the Chennai Urban Rural Epidemiology Study. Metabolism 55:237–242

    PubMed  CAS  Google Scholar 

  75. Angelico F, Alessandri C, Ferro D et al (2006) Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation. Diabetologia 49:1169–1174

    PubMed  CAS  Google Scholar 

  76. Marx N (2002) Peroxisome proliferator-activated receptor gamma and atherosclerosis. Curr Hypertens Rep 4:71–77

    PubMed  Google Scholar 

  77. Jiang C, Ting AT, Seed B (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82–86

    PubMed  CAS  Google Scholar 

  78. Akbiyik F, Ray DM, Gettings KF et al (2004) Human bone marrow megakaryocytes and platelets express PPAR-γ, and PPAR-γ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104:1361–1368

    PubMed  CAS  Google Scholar 

  79. Blake GJ, Ridker PM (2000) Are statins anti-inflammatory? Curr Control Trial Cardiovasc Med 1:161–165

    CAS  Google Scholar 

  80. Shishehbor MH, Brennan ML, Aviles RJ et al (2003) Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108:426–431

    PubMed  CAS  Google Scholar 

  81. Schönbeck U, Gerdes N, Varo N et al (2002) Oxidized low-density lipoprotein augments and 3-hydroxy-3-mathylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 106:2888–2893

    PubMed  Google Scholar 

  82. Wagner AH, Gebauer M, Guldenzoph B, Hecker M (2002) 3-Hydroxy-3-mathylglutaryl coenzyme A reductase-independent inhibition of CD40L expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol 22:1784–1789

    PubMed  CAS  Google Scholar 

  83. Mulhaupt F, Matter CM, Kwak BR et al (2003) Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 59:755–766

    PubMed  CAS  Google Scholar 

  84. Wang TD, Chen WJ, Lin JW et al (2003) Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170:315–323

    PubMed  CAS  Google Scholar 

  85. Semb AG, van Wissen S, Ueland T et al (2003) Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 41:275–279

    PubMed  CAS  Google Scholar 

  86. Han SH, Koh KK, Quon MJ et al (2007) The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients. Atherosclerosis 190:205–211

    PubMed  CAS  Google Scholar 

  87. Hwang YS, Tsai WC, Lu YH et al (2004) Effect of atorvastatin on the expression of CD40 ligand and P-selection on platelets in patients with hypercholesterolemia. Am J Cardiol 94:364–366

    PubMed  CAS  Google Scholar 

  88. Alber HF, Frick M, Suessenbacher A et al (2006) Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease — a randomized, placebo-controlled study. Am Heart J 151:139

    PubMed  Google Scholar 

  89. Li J, Zhao SP, Peng DQ et al (2004) Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction. Clin Chem 50:1696–1699

    PubMed  CAS  Google Scholar 

  90. Mitsios JV, Papathanasiou AI, Rodis FI et al (2004) Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 109:1335–1338

    PubMed  CAS  Google Scholar 

  91. Kinlay S, Schwartz GG, Olsson AG et al (2004) Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110:386–391

    PubMed  CAS  Google Scholar 

  92. Pignatelli P, Sanguigni V, Lenti L et al (2004) gp91phoxdependent expression of platelet CD40 ligand. Circulation 110:1326–1329

    PubMed  CAS  Google Scholar 

  93. Pignatelli P, Sanguigni V, Paola SG et al (2005) Vitamin C inhibits platelet expression of CD40 ligand. Free Radic Biol Med 38:1662–1666

    PubMed  CAS  Google Scholar 

  94. Schönbeck U, Varo N, Libby P et al (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268

    PubMed  Google Scholar 

  95. Hermann A, Rauch BH, Braun M et al (2001) Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 12:74–82

    PubMed  CAS  Google Scholar 

  96. Bhatt DL, Topol EJ (2003) Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2:15–28

    PubMed  CAS  Google Scholar 

  97. Quinn MJ, Bhatt DL, Zidar F et al (2004) Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 93:679–684

    PubMed  CAS  Google Scholar 

  98. Azar RR, Kassab R, Zoghbi A et al (2006) Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 151:521.e1–521.e4

    CAS  Google Scholar 

  99. Xiao Z, Theroux P (2004) Clopidogrel inhibits plateletleukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 43:1982–1988

    PubMed  CAS  Google Scholar 

  100. Yip HK, Chang LT, Sun CK et al (2006) Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. Am J Cardiol 97:192–194

    PubMed  CAS  Google Scholar 

  101. Azar RR, Badaoui G, Sarkis A et al (2005) Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease. Am J Cardiol 95:236–240

    PubMed  CAS  Google Scholar 

  102. Mo VY, De Lemos JA (2004) Individualizing therapy in acute coronary syndromes: using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy. Curr Cardiol Rep 6:273–278

    PubMed  CAS  Google Scholar 

  103. Conde ID, Kleiman NS (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 384:2575–2576

    Google Scholar 

  104. Bereczki D, Nagy E, Pal A et al (2003) Should soluble CD40 ligand be measured from serum or plasma samples? Arterioscler Thromb Vasc Biol 23:1129–1130

    PubMed  CAS  Google Scholar 

  105. Ahn ER, Lander G, Jy W et al (2004) Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114:143–148

    PubMed  CAS  Google Scholar 

  106. Thom J, Gilmore G, Yi Q et al (2004) Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost 2:2067–2069

    PubMed  CAS  Google Scholar 

  107. Halldorsdottir AM, Stoker J, Porche-Sorbet R, Eby CS (2005) Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method. Clin Chem 51:1054–1057

    PubMed  CAS  Google Scholar 

  108. Varo N, Nuzzo R, Natal C et al (2006) Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci (Lond) 111:341–347

    Article  CAS  Google Scholar 

  109. Weber M, Rabenau B, Stanisch M et al (2006) Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin Chem 52:888–891

    PubMed  CAS  Google Scholar 

  110. Lessiani G, Falco A, Dragani A et al (2006) Polycythemia vera and endothelial dysfunction: role of CD40 ligand. Atherosclerosis Suppl 7:88

    Google Scholar 

  111. Anand SX, Viles-Gonzalez JF, Badimon JJ et al (2003) Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 90:377–384

    PubMed  CAS  Google Scholar 

  112. Verma S, Wang CH, Li SH et al; FATE Investigators (2005) The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. Atherosclerosis 182:361–365

    PubMed  CAS  Google Scholar 

  113. de Lemos JA, Zirlik A, Schonbeck U et al (2005) Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 25:2192–2196

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center of Excellence on Aging, University of Chieti “G. D’Annunzio” School of Medicine, Via Colle dell’Ara, I-66013, Chieti, Italy

    F. Santilli & G. Davì

  2. Department of Medical Therapy, University of Rome “La Sapienza”, Rome, Italy

    S. Basili

  3. Department of Laboratory Medicine & Advanced Biotechnologies, IRCCS San Raffaele, Rome, Italy

    P. Ferroni

Authors
  1. F. Santilli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Basili
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Ferroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Davì
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Davì.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Santilli, F., Basili, S., Ferroni, P. et al. CD40/CD40L system and vascular disease. Int Emergency Med 2, 256–268 (2007). https://doi.org/10.1007/s11739-007-0076-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-007-0076-0

Keywords

Search

Navigation